View Financial HealthThis company has been acquiredThe company may no longer be operating, as it has been acquired. Find out why through their latest events.See Latest EventsCardiovascular Systems 配当と自社株買い配当金 基準チェック /06主要情報n/a配当利回り-0.2%バイバック利回り総株主利回り-0.2%将来の配当利回り0%配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesSecond quarter 2023 earnings: EPS and revenues miss analyst expectations Feb 09Abbott Laboratories (NYSE:ABT) entered into a definitive agreement to acquire Cardiovascular Systems, Inc. (NasdaqGS:CSII) for approximately $880 million.Feb 09We're Not Very Worried About Cardiovascular Systems' (NASDAQ:CSII) Cash Burn RateFeb 03Cardiovascular Systems, Inc. to Report Q2, 2023 Results on Feb 09, 2023Jan 20Cardiovascular Systems, Inc. Enrolls First Patient in Japan for Kaizen Clinical StudyJan 12Price target decreased to US$21.20 Dec 22Insufficient new directors Dec 02First quarter 2023 earnings: EPS misses analyst expectations Nov 04Cardiovascular Systems, Inc. Provides Earnings Guidance for the Year Ending June 30, 2023Nov 04Cardiovascular Systems, Inc. Announces Full Market Release of the 2.00 Max Crown for Peripheral Orbital Atherectomy SystemsOct 18Cardiovascular Systems, Inc. to Report Q1, 2023 Results on Nov 03, 2022Oct 13We're Hopeful That Cardiovascular Systems (NASDAQ:CSII) Will Use Its Cash WiselyOct 12Cardiovascular Systems, Inc., Annual General Meeting, Nov 08, 2022Sep 29Full year 2022 earnings: EPS misses analyst expectations Aug 04Cardiovascular Systems, Inc. Provides Earnings Guidance for the Year Ending June 30, 2023Aug 03Cardiovascular Systems reports Q4 earnings miss; provides FY23 revenue guidance in-line with estimates Aug 03Cardiovascular Systems, Inc. to Report Q4, 2022 Results on Aug 02, 2022Jul 14Cardiovascular Systems, Inc.(NasdaqGS:CSII) dropped from Russell 2000 Growth-Defensive IndexJun 26+ 1 more updateThird quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind May 05Cardiovascular Systems, Inc. Provides Earnings Guidance for the Fiscal Year 2022May 05Price target decreased to US$23.50 Apr 27Cardiovascular Systems, Inc. to Report Q3, 2022 Results on May 04, 2022Apr 14Cardiovascular Systems, Inc. Announces Ryan Egeland Employment Would End as Chief Medical OfficerMar 06+ 1 more updateConsensus revenue estimates fall by 10% Feb 10Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Feb 04Cardiovascular Systems, Inc. Provides Earnings Guidance for the Fiscal Year Ending June 30, 2022Feb 04Cardiovascular Systems, Inc. Along with Orbusneich Medical Company Ltd, Announces FDA PMA Approval of Orbusneich’s Scoreflex®NC Scoring Percutaneous Transluminal Coronary Angioplasty CatheterJan 22Cardiovascular Systems, Inc. Announces Development of Intravascular Lithotripsy Technology for the Treatment of Coronary and Peripheral Artery DiseasesJan 14No longer forecast to breakeven Nov 25First quarter 2022 earnings released: US$0.22 loss per share (vs US$0.054 loss in 1Q 2021) Nov 11Price target decreased to US$41.50 Nov 10Here's Why Cardiovascular Systems, Inc.'s (NASDAQ:CSII) CEO Compensation Is The Least Of Shareholders' ConcernsNov 05Are Investors Undervaluing Cardiovascular Systems, Inc. (NASDAQ:CSII) By 36%?Oct 09Cardiovascular Systems, Inc. Announces First Patient Treated with ViperCross Peripheral Support CatheterOct 02At US$36.59, Is It Time To Put Cardiovascular Systems, Inc. (NASDAQ:CSII) On Your Watch List?Sep 18Consensus forecasts updated Aug 18Consensus forecasts updated Aug 11Full year 2021 earnings released: US$0.35 loss per share (vs US$0.80 loss in FY 2020) Aug 05Are Investors Undervaluing Cardiovascular Systems, Inc. (NASDAQ:CSII) By 28%?Jun 24Is Now The Time To Look At Buying Cardiovascular Systems, Inc. (NASDAQ:CSII)?Jun 03Cardiovascular Systems, Inc. Announces U.S. Commercial Launch of JADE Over-the-Wire Non-Compliant Peripheral Balloon CathetersJun 02Cardiovascular Systems, Inc Announces Results from a Real-World Optical Coherence TomographyMay 21Independent Director recently bought US$52k worth of stock May 13Cardiovascular Systems, Inc. Provides Earnings Guidance for the Fourth Quarter Ending June 30, 2021May 08Third quarter 2021 earnings released: US$0.15 loss per share (vs US$0.085 loss in 3Q 2020) May 07We're Interested To See How Cardiovascular Systems (NASDAQ:CSII) Uses Its Cash Hoard To GrowApr 29Cardiovascular Systems, Inc. Announces First Uses of WIRION® Embolic Protection SystemMar 18Should You Take Comfort From Insider Transactions At Cardiovascular Systems, Inc. (NASDAQ:CSII)?Mar 17Cardiovascular Systems (NASDAQ:CSII) Shareholders Have Enjoyed A Whopping 399% Share Price GainFeb 10First Patient in Europe Treated With Cardiovascular Systems, Inc. Diamondback 360® Coronary Orbital Atherectomy SystemFeb 09Earnings beat expectations, revenue disappoints Feb 08Second quarter 2021 earnings released: US$0.001 loss per share (vs US$0.10 loss in 2Q 2020) Feb 06Cardiovascular Systems, Inc. Announces Partnership with Chansu Vascular Techologies, Llc to Develop New Drug-Coated Balloon TechnologyFeb 02Cardiovascular Systems, Inc. Elects Sachin Jain as a Class II DirectorJan 28New 90-day high: US$46.79 Jan 22Cardiovascular Systems, Inc. to Report Q2, 2021 Results on Feb 03, 2021Jan 14New 90-day high: US$44.30 Jan 06New 90-day high: US$39.84 Dec 17Need To Know: Cardiovascular Systems, Inc. (NASDAQ:CSII) Insiders Have Been Selling SharesDec 11Analysts update estimates Nov 12Revenue beats expectations, earnings disappoint Nov 06First quarter 2021 earnings released: US$0.054 loss per share Nov 06Cardiovascular Systems to Present Data from Large Coronary Orbital Atherectomy Study at the TCT Connect 2020 ConferenceOct 08New 90-day high: US$39.35 Oct 01Cardiovascular Systems Inc. signed a definitive agreement to acquire Replidyne, Inc. (NasdaqGM: RDYN) in a reverse merger transaction.Sep 18Cardiovascular Systems, Inc. to Report Q4, 2020 Results on Aug 04, 2020Jul 17決済の安定と成長配当データの取得安定した配当: CSIIの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: CSIIの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Cardiovascular Systems 配当利回り対市場CSII 配当利回りは市場と比べてどうか?セグメント配当利回り会社 (CSII)n/a市場下位25% (US)1.4%市場トップ25% (US)4.3%業界平均 (Medical Equipment)2.2%アナリスト予想 (CSII) (最長3年)0%注目すべき配当: CSIIは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: CSIIは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: CSIIの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: CSIIが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YUS 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日(UTC時間)企業分析2023/04/27 15:37終値2023/04/27 00:00収益2022/12/31年間収益2022/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM(Trailing Twelve Month)またはLTM(Last Twelve Month)データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Cardiovascular Systems, Inc. 6 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。17 アナリスト機関Nathan WeinsteinAegis Capital CorporationLawrence NeiborBairdMatthew MiksicBarclays14 その他のアナリストを表示
Abbott Laboratories (NYSE:ABT) entered into a definitive agreement to acquire Cardiovascular Systems, Inc. (NasdaqGS:CSII) for approximately $880 million.Feb 09
Cardiovascular Systems, Inc. Announces Full Market Release of the 2.00 Max Crown for Peripheral Orbital Atherectomy SystemsOct 18
Cardiovascular Systems reports Q4 earnings miss; provides FY23 revenue guidance in-line with estimates Aug 03
Cardiovascular Systems, Inc.(NasdaqGS:CSII) dropped from Russell 2000 Growth-Defensive IndexJun 26+ 1 more update
Cardiovascular Systems, Inc. Announces Ryan Egeland Employment Would End as Chief Medical OfficerMar 06+ 1 more update
Cardiovascular Systems, Inc. Provides Earnings Guidance for the Fiscal Year Ending June 30, 2022Feb 04
Cardiovascular Systems, Inc. Along with Orbusneich Medical Company Ltd, Announces FDA PMA Approval of Orbusneich’s Scoreflex®NC Scoring Percutaneous Transluminal Coronary Angioplasty CatheterJan 22
Cardiovascular Systems, Inc. Announces Development of Intravascular Lithotripsy Technology for the Treatment of Coronary and Peripheral Artery DiseasesJan 14
Here's Why Cardiovascular Systems, Inc.'s (NASDAQ:CSII) CEO Compensation Is The Least Of Shareholders' ConcernsNov 05
Cardiovascular Systems, Inc. Announces First Patient Treated with ViperCross Peripheral Support CatheterOct 02
Cardiovascular Systems, Inc. Announces U.S. Commercial Launch of JADE Over-the-Wire Non-Compliant Peripheral Balloon CathetersJun 02
Cardiovascular Systems, Inc. Provides Earnings Guidance for the Fourth Quarter Ending June 30, 2021May 08
Should You Take Comfort From Insider Transactions At Cardiovascular Systems, Inc. (NASDAQ:CSII)?Mar 17
Cardiovascular Systems (NASDAQ:CSII) Shareholders Have Enjoyed A Whopping 399% Share Price GainFeb 10
First Patient in Europe Treated With Cardiovascular Systems, Inc. Diamondback 360® Coronary Orbital Atherectomy SystemFeb 09
Cardiovascular Systems, Inc. Announces Partnership with Chansu Vascular Techologies, Llc to Develop New Drug-Coated Balloon TechnologyFeb 02
Cardiovascular Systems to Present Data from Large Coronary Orbital Atherectomy Study at the TCT Connect 2020 ConferenceOct 08
Cardiovascular Systems Inc. signed a definitive agreement to acquire Replidyne, Inc. (NasdaqGM: RDYN) in a reverse merger transaction.Sep 18